142 related articles for article (PubMed ID: 17161453)
1. Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6).
Wagner U; du Bois A; Pfisterer J; Huober J; Loibl S; Lück HJ; Sehouli J; Gropp M; Stähle A; Schmalfeldt B; Meier W; Jackisch C;
Gynecol Oncol; 2007 Apr; 105(1):132-7. PubMed ID: 17161453
[TBL] [Abstract][Full Text] [Related]
2. Phase 2 trial of carboplatin plus tamoxifen in platinum-resistant ovarian cancer and primary carcinoma of the peritoneum.
Markman M; Webster K; Zanotti K; Peterson G; Kulp B; Belinson J
Gynecol Oncol; 2004 Aug; 94(2):404-8. PubMed ID: 15297180
[TBL] [Abstract][Full Text] [Related]
3. Pilot study evaluating the efficacy and toxicity of irinotecan plus oral etoposide for platinum- and taxane-resistant epithelial ovarian cancer.
Nishio S; Sugiyama T; Shouji T; Yoshizaki A; Kitagawa R; Ushijima K; Kamura T
Gynecol Oncol; 2007 Aug; 106(2):342-7. PubMed ID: 17499346
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study.
Hurteau JA; Brady MF; Darcy KM; McGuire WP; Edmonds P; Pearl ML; Ivanov I; Tewari KS; Mannel RS; Zanotti K; Benbrook DM
Gynecol Oncol; 2010 Dec; 119(3):444-50. PubMed ID: 20846715
[TBL] [Abstract][Full Text] [Related]
5. Phase 2 trial of prolonged administration of oral topotecan in platinum/taxane-refractory ovarian, fallopian tube, and primary peritoneal cancers.
Markman M; Webster K; Zanotti K; Kulp B; Peterson G; Belinson J
Gynecol Oncol; 2004 Oct; 95(1):109-13. PubMed ID: 15385118
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of oral etoposide plus intravenous irinotecan in patients with platinum-resistant and taxane-pretreated ovarian cancer (JCOG0503).
Matsumoto K; Katsumata N; Shibata T; Satoh T; Saitou M; Yunokawa M; Takano T; Nakamura K; Kamura T; Konishi I
Gynecol Oncol; 2015 Feb; 136(2):218-23. PubMed ID: 25449313
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube.
Noguera IR; Sun CC; Broaddus RR; Branham D; Levenback CF; Ramirez PT; Sood AK; Coleman RL; Gershenson DM
Gynecol Oncol; 2012 Jun; 125(3):640-5. PubMed ID: 22387451
[TBL] [Abstract][Full Text] [Related]
8. A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer.
Clamp A; Adams M; Atkinson R; Boven E; Calvert AH; Cervantes A; Ganesan T; Lotz J; Vasey P; Cheverton P; Jayson GC
Gynecol Oncol; 2004 Oct; 95(1):114-9. PubMed ID: 15385119
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074).
Pautier P; Joly F; Kerbrat P; Bougnoux P; Fumoleau P; Petit T; Rixe O; Ringeisen F; Carrasco AT; Lhommé C
Gynecol Oncol; 2010 Feb; 116(2):157-62. PubMed ID: 20109725
[TBL] [Abstract][Full Text] [Related]
10. Single nedaplatin treatment as salvage chemotherapy for platinum/taxane-resistant/refractory epithelial ovarian, tubal and peritoneal cancers.
Goto T; Takano M; Ohishi R; Iwasa N; Shimizu M; Hasegawa K; Nagao S; Fujiwara K
J Obstet Gynaecol Res; 2010 Aug; 36(4):764-8. PubMed ID: 20666942
[TBL] [Abstract][Full Text] [Related]
11. Docetaxel/irinotecan combination chemotherapy in platinum/taxane-refractory and -resistant ovarian cancer: JGOG/WJGOG Intergroup Study.
Ushijima K; Kamura T; Tamura K; Kuzuya K; Sugiyama T; Noda K; Ochiai K
Int J Clin Oncol; 2013 Feb; 18(1):126-31. PubMed ID: 22127346
[TBL] [Abstract][Full Text] [Related]
12. Sequential topotecan and oral etoposide in recurrent ovarian carcinoma pretreated with platinum-taxane. Results from a multicenter phase I/II study.
Gronlund B; Engelholm SA; Horvath G; Mäenpää J; Ridderheim M
Cancer; 2005 Apr; 103(7):1388-96. PubMed ID: 15719439
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of AEZS-108 (INN: zoptarelin doxorubicin acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: a multicenter phase II trial of the ago-study group (AGO GYN 5).
Emons G; Gorchev G; Sehouli J; Wimberger P; Stähle A; Hanker L; Hilpert F; Sindermann H; Gründker C; Harter P
Gynecol Oncol; 2014 Jun; 133(3):427-32. PubMed ID: 24713545
[TBL] [Abstract][Full Text] [Related]
14. Oxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: a phase II study.
Pectasides D; Pectasides M; Farmakis D; Gaglia A; Koumarianou A; Nikolaou M; Koumpou M; Kountourakis P; Papaxoinis G; Mitrou P; Economopoulos T; Raptis SA
Gynecol Oncol; 2004 Oct; 95(1):165-72. PubMed ID: 15385127
[TBL] [Abstract][Full Text] [Related]
15. A phase II trial of oral capecitabine in patients with platinum--and taxane--refractory ovarian, fallopian tube, or peritoneal cancer.
Wolf JK; Bodurka DC; Verschraegen C; Sun CC; Branham D; Jenkins AD; Atkinson N; Gershenson DM
Gynecol Oncol; 2006 Sep; 102(3):468-74. PubMed ID: 16516276
[TBL] [Abstract][Full Text] [Related]
16. Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.
Fu S; Hennessy BT; Ng CS; Ju Z; Coombes KR; Wolf JK; Sood AK; Levenback CF; Coleman RL; Kavanagh JJ; Gershenson DM; Markman M; Dice K; Howard A; Li J; Li Y; Stemke-Hale K; Dyer M; Atkinson E; Jackson E; Kundra V; Kurzrock R; Bast RC; Mills GB
Gynecol Oncol; 2012 Jul; 126(1):47-53. PubMed ID: 22487539
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC).
Gadgeel SM; Ruckdeschel JC; Heath EI; Heilbrun LK; Venkatramanamoorthy R; Wozniak A
J Thorac Oncol; 2007 Apr; 2(4):299-305. PubMed ID: 17409801
[TBL] [Abstract][Full Text] [Related]
18. Tumor inhibitory effect of gefitinib (ZD1839, Iressa) and taxane combination therapy in EGFR-overexpressing breast cancer cell lines (MCF7/ADR, MDA-MB-231).
Takabatake D; Fujita T; Shien T; Kawasaki K; Taira N; Yoshitomi S; Takahashi H; Ishibe Y; Ogasawara Y; Doihara H
Int J Cancer; 2007 Jan; 120(1):181-8. PubMed ID: 17036319
[TBL] [Abstract][Full Text] [Related]
19. Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis : a Hoosier Oncology Group trial.
Matei D; Emerson RE; Schilder J; Menning N; Baldridge LA; Johnson CS; Breen T; McClean J; Stephens D; Whalen C; Sutton G
Cancer; 2008 Aug; 113(4):723-32. PubMed ID: 18618737
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan.
Verschraegen CF; Kudelka AP; Hu W; Vincent M; Kavanagh JJ; Loyer E; Bastien L; Duggal A; De Jager R
Cancer Chemother Pharmacol; 2004 Jan; 53(1):1-7. PubMed ID: 14586557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
